2′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases

US9061041B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Vinay M. Girijavallabhan · Woburn, US
• F. George Njoroge · Hackettstown, US
• Stephane L. Bogen · Somerville, US
• Vishal Verma · San Francisco, US
• Frank Bennett · Piscataway, US
• Angela Dawn Kerekes · Plainfield, US
• Ashok Arasappan · Bound Brook, US
• Dmitri Pissarnitski · Scotch Plains, US
• Qun Dang · Westfield, US
• Ian Davies · Princeton, US
• David B. Olsen · Johnstown, US
• Andrew Stamford · Madison, US
• Joseph P. Vacca · Telford, US

Key dates

• Filing date: Apr 11, 2012
• Grant date: Jun 23, 2015
• Expiry date: Apr 11, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07H19/213
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to 2′-Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, X, R1, R2 and R3 are as defined herein. The present invention also relates to compositions comprising at least one 2′-Substituted Nucleoside Derivative, and methods of using the 2′-Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.